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Abstract
The T cell leukaemia/lymphoma 1A (TCL1A) oncoprotein plays key roles in several B and T cell malignancies. Lacking
enzymatic activity, TCL1A’s transforming action was linked to its capacity to co-activate the protein kinase AKT via binding
to its pleckstrin homology (PH) domain. However, perturbation of AKT signalling alone was recently shown insufficient to
explain TCL1A oncogenesis, suggesting that TCL1A has additional cellular partners. Searching for such additional targets, we
found that TCL1A binds specifically and directly to the ankyrin domain of IkB, the inhibitor of the NF-kB transcription
factors. Through binding assays and a structural analysis by small angle X-ray scattering, we show that TCL1A and IkB
interact in yeast-two-hybrid systems, when transiently overexpressed in 293 cells, and as recombinant proteins in vitro.W e
further establish that the association between TCL1A and IkB is compatible with AKT binding to TCL1A, but incompatible
with IkB binding to NF-kB. By interfering with the inhibition of NF-kBb yI kB, TCL1A may increase the concentration of free
NF-kB molecules sufficiently to trigger expression of anti-apoptotic genes. Thus our data suggest an additional route by
which TCL1A might cause cancer.
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Introduction
TCL1-family proteins (TCL1A, TCL1B and MTCP1 in
humans) are 13–15 kDa non-enzymatic interaction modules.
Their restricted physiological expression and apparent lack of
auto-regulatory mechanisms suggest that they are mainly regulat-
ed by tightly controlled gene expression levels. Normal time- and
tissue-restricted expression of TCL1 genes is important for efficient
fertility, and the development of T and B cell lineages.
Deregulation of TCL1 expression can cause the transformation
of mature human T and B lymphocytes, and is associated with a
variety of human diseases, including T-cell prolymphocytic
leukaemia, B-cell chronic leukaemia (B-CLL), B-cell lymphoma
and germ-cell tumours [reviewed in [1,2]].
TCL1A is a co-activator of AKT, a serine/threonine protein
kinase that regulates many cellular processes, including prolifer-
ation and survival [3,4]. TCL1A forms homodimers, and each
protomer binds one pleckstrin homology (PH) domain of AKT [5].
Co-activation may thus result from stabilising AKT in an open
(active) conformation, from promoting AKT auto-phosphorylation
in trans, and/or from reinforcing AKT attachment to the
membrane, where its effectors are located [1,2]. Activated AKT
can promote cell survival by phosphorylating downstream targets
such as BAD [6]. AKT can also activate the NF-kB transcription
factor, possibly by phosphorylating the IkB kinase (IKK)[7].
Phosphorylated IKK phosphorylates IkB, leading to dissociation
of the IkB:NF-kB complex. Liberated NF-kB subsequently
translocates to the nucleus to activate survival-inducing genes [8].
However, the effects of TCL1A on AKT are insufficient to fully
explain TCL1A oncogenesis. For example, AKT phosphorylation
or inactivation kinetics do not consistently relate to TCL1A
expression in both transgenic mice and patient–derived neoplasia,
and AKT activation alone does not necessarily cause tumours in B
cells [1]. This suggests that additional effects, and effectors, of
TCL1A exist. Recently, it was reported that the NF-kB pathway is
important for B-CLL in transgenic mouse models (reviewed in
[9]), and that TCL1A activates NF-kB through an AKT-
independent route [10]. Corroborating an AKT-independent
targeting of NF-kB by TCL1A, we here report that TCL1A binds
directly to the NF-kB inhibitor IkB.
Results
In a search for additional partners of TCL1A, we identified IkBa
through yeast two-hybrid screening. The prey consisted of residues
73–317 of IkBa, and included the six ankyrin repeats that bind NF-
kB [11,12] (Figure 1a). After over-expression of IkBa and FLAG-
TCL1A in 293 cells, IkBa coimmunoprecipitated with TCL1A,
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(Figure 1b). GST-TCL1A interacted significantly more strongly
with IkBa than did GST-MTCP1 (Figure 1c). Conversely, two-
hybrid, gel shift, and fluorescence anisotropy assays failed to detect
an interaction between MTCP1 and IkBa (data not shown). In vitro,
GST-TCL1A bound the AKTb PHdomain(AKT_PH;residues 1–
118), and an all-cysteine-to-serine (7CS) mutant of the IkBa ankyrin
domain (IkB_ank, residues 67–302; the C-.S substitutions were
made to avoid non-specific aggregation through cys-cys di-sulphide
bridges), but not the ankyrin domain of the Drosophila signalling
protein Notch (Figure S1a).
Native SDS PAGE gel shift assays showed that AKT_PH,
IkB_ank and IkB_ank
7CS retarded migration of TCL1A (Figure 2,
Figure S1b,c). Using isothermal titration calorimetry (ITC),
TCL1A displayed a dissociation constant (KD) of 7.561.0 mM
for AKT_PH, in agreement with previous NMR measurements
[5] (Table 1, and Figure S2a). TCL1A bound IkB_ank
7CS with a
KD of 0.7160.07 mM (Figure 3). Placing the 1:1 TCL1A:Ik-
B_ank
7CS complex in the ITC cell slightly increased the affinity of
injected AKT_PH (KD=5.160.5 mM), as compared to titrations
with only TCL1A in the cell. This showed that binding of IkB_ank
and AKT_PH to TCL1A are compatible and slightly cooperative
events (Figure S2b). Conversely, when the cell was filled with
IkB_ank
7CS bound to the NF-kB family member RELA, injection
of TCL1A yielded curves with a KD&50 mM, inferring that
binding of TCL1A and RELA to IkB_ank are incompatible events
(data not shown). Competition between TCL1A and RELA for
IkB_ank was confirmed by gel shift assays (Figure 2c).
In the absence of successful TCL1A:IkB crystallisation trials, we
used small angle X-ray scattering (SAXS) to obtain structural
information on the complex. Guinier analysis and data processing
by GNOM [13] established a radius of gyration of 4.560.2 nm
and a maximum diameter of 15.060.5 nm. The P(r) distance
distribution obtained for TCL1A:IkB_ank
7CS displayed a trian-
gular shape indicative for an elongated particle (Figure S3a). Initial
ab initio shape calculations with DAMMIN [13] without symmetry
constraints yielded elongated particles with a volume of
12.7610
4 A ˚ 3, comparable to the one of a 26(TCL1A:IkB_ank)
complex (11.0610
4 A ˚ 3, calculated without hydration shell). The
Z-shape of these reconstructions was suggestive of a P2 symmetry
(data not shown). Because TCL1A forms stable dimers in solution
[5,14], we subsequently used P2 symmetry for iterative ab initio
shape reconstructions with the program GASBOR [15]. The best
scored ab initio structure out of 40 individual GASBOR runs fitted
data between q=0.02 and 0.45 A ˚ 21 with a x value of 1.02
(CRYSOL [16]; Figure S3b). This SAXS envelope is composed of
a trapeze-shaped central domain, and two laterally attached rod-
like domains (Figure 4b). The dimensions of the central and rod-
like domains correspond to those of the crystal structures of the
TCL1A dimer [14] and IkB_ank monomer [11,12], respectively.
The ab inito shape suggested that TCL1A binds either to the N- or
C-terminal ankyrin repeats of IkB_ank. Since the C-terminal sixth
ankyrin repeat of IkBa was dispensable for binding (Figure 1d),
our analysis supports that TCL1A principally contacts the first N-
terminal ankyrin repeats of IkBa.
We next used the crystal structures of TCL1A and IkB_ank to
perform SAXS-guided rigid body docking with the program
SASREF [13]. The information that TCL1A binds to the N- and
not the C-terminal of IkB_ank was used as a constraint. The best-
scored 20 structures out of 100 individual Monte-Carlo-based
simulated annealing calculations were averaged using DAMAVER
[17]. The representative structure determined by DAMAVER,
which was also the one with the best fit of all SASREF runs (x fit to
data between q=0.02 and 0.40 A ˚ 21 was 1.02; Figure 4a),
corresponded well to the ab initio GASBOR envelope (Figure 4b).
Rg and Dm values for this structure (42.3 A ˚ and 144.2 A ˚,
respectively, calculated without hydration shell) were in good
agreement with values obtained from GNOM and Guinier
analysis for the hydrated particle (4.560.2 nm and 15.060.5 nm).
Our structural analysis suggests that TCL1A uses a binding site
roughly opposite to its dimerisation site to interact with the first
one or two ankyrin repeats of IkB_ank. Thus TCL1A may
compete with helices aA and aB of RELA [11,12]. The IkB_ank
binding site is close to, but not overlapping with, the AKT_PH
binding surface on TCL1A [5], corroborating that TCL1A can
bind IkB and AKT simultaneously.
Discussion
Several lines of evidence suggest an AKT-independent action of
TCL1A on NF-kB pathways [9,10,18]. We here sharpened this
picture by showing that TCL1A and the NF-kB inhibitor IkB
associate in vitro, in yeast-two-hybrid systems, and when transiently
overexpressed in 293 cells. We also showed in vitro that TCL1A
competed with NF-kB for binding to IkB, suggesting that TCL1A
interferes with the inhibitory interaction between IkB and NF-kB.
Figure 1. Cell-based binding assays. (a) Schematic representation
of IkBa. (b) Co-immunoprecipitation assay. Input 2%: 2% of the whole
extract used for the immunoprecipitation. IP control: Immunoprecipi-
tation with irrelevant antibody (anti-HA). (c,d) [
35S]-labeled IkBa or
IkBa1–253 produced by in vitro transcription/translation in rabbit
reticulocytes lysate, were incubated with GST, GST-MTCP1 and GST-
TCL1A immobilized on glutathione-sepharose beads. Bound proteins
were resolved by 12% SDS-PAGE and detected by autoradiography.
doi:10.1371/journal.pone.0006567.g001
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which also interact with helices aA and aB of RELA [11,12], it is
likely that TLC1A and RELA use overlapping binding sites on
IkB. However, we can not exclude that IkB binding to one partner
causes conformational changes (such as a slight change in the
curvature of the ankyrin repeats) that affect allosterically the
(distant) binding site of the other partner.
On a cellular level, the effect expected to arise from the
competition of TCL1A and NF-kBf o rI kBw o u l db ea nA K T -
independent NF-kB-activation by TCL1A. This was indeed recently
observed by Pekarsky et al. [10]. These authors reported that this
effect involves the association between TCL1A and p300. The
molecular details of the association between TCL1A and p300
remain elusive. Since both proteins are multivalent adaptor proteins,
sequential or concomitant interactions of TCL1A with IkBa r en o t
excluded, and may be necessary for activation of NF-kB.
The description of several AKT-independent TCL1A targets
suggests that TCL1A affects a number of alternative and
interconnected signalling pathways ([10,18], and this report).
Indeed, depending on the cell type and experimental conditions,
both NF-kB activation and inhibition by TCL1A were reported, as
well as alternative, NF-kB independent routes (inhibition of PKCh
and ERK activation, or of AP-1 transcriptional activity) [10,18].
Thus, TCL1A increasingly appears as a polyvalent adaptor protein,
whose cellular action is dramatically affected by its sub-cellular
concentration and the availability of potential targets.
The affinity we measured between IkB and TCL1A was about
1,000 fold weaker than the one previously reported between IkB
and NF-kB [19]. However, since only a minor fraction of
cytoplasmic NF-kB is enough to trigger transcriptional activation
[20], even weak competition by TCL1A is expected to alter gene
expression through NF-kB. Yet this effect will be caused by only a
negligible fraction of cellular IkB and NF-kB, which may explain
why we were unable to detect significant amounts of TCL1A-IkB
complexes in absence of transient overexpression, as searched for
in 697 and Sup-T11 TCL1-positive leukaemic cell lines (data not
shown). In addition, a biologically significant effect on the IkB:NF-
kB complex is likely to require TCL1A over-expression following
chromosomal translocation, and/or additional factors, such as
AKT, p300, or factors associated with a particular cell activation
level. Importantly, TCL1A also needs co-stimulatory signals to
induce AKT activation (possibly the association of AKT_PH with
PIP3 [2,3]), and the requirement of co-activators may constitute an
additional control mechanism for TCL1A.
Given that TCL1A binds IkB and AKT_PH simultaneously in
vitro, TCL1A may act on IkB and AKT synergistically or
independently. In its physiological location, the 59 promoter
region of the TCL1A gene contains, among others, an NF-kB-
responsive cis-regulatory element [7]. Through the action of
TCL1A on IkB or AKT, this element may produce a positive
feed-back loop to enhance TCL1A expression. Thus, the
Figure 2. Native gel shift assays. (a–c): Bands corresponding to the complexes formed are indicated on the right of each figure. (b,c): The three
lanes on the right correspond to increasing concentrations of IkB_ank
7CS (b) or RELA (c).
doi:10.1371/journal.pone.0006567.g002
Table 1. Summary of ITC data.
Syringe/Cell KD (mM) N
DH
(kJ/mol)
TDS
(kJ/mol)
DG
(kJ/mol)
AKT_PH/TCL1A 7.561.0 0.760.3
a 260.962.5 229.9 231.0
AKT_PH/TCL1A:IkB5 . 1 60.5 0.760.3
a 239.061.2 29.4 229.7
TCL1A/IkB 0.7160.07 0.960.1 253.260.5 217.9 235.3
TCL1A/IkB:RELA &50 n.d. n.d. n.d. n.d.
n.d.: not determined.
aA 1:1 stoichiometry can be deduced from our previous analyses [5].
doi:10.1371/journal.pone.0006567.t001
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transcriptional regulation of TCL1A.
Future research will be necessary to clarify the in vivo significance
and role of the TCL1A-IkB interaction for oncogenesis. However,
given that TCL1A appears to be a polyvalent adaptor protein with
multiple cellular partners, it will be far from trivial to design a cell-
based assay that allows observing a molecular effect based solely on
this TCL1A-IkB interaction. Moreover, because only an extremely
low fraction of cellular IkB:NF-kB complexes is predicted to be
affected by TCL1A, it will be difficult to use intracellular detection
methods based on endogenous protein (for example co-localisation
studies by immunofluorescence, or co-immunoprecipation experi-
ments). The identification of potential binding surfaces by our
structural characterisation of the TCL1A-IkB interaction may
however help resolving these issues.
Materials and Methods
Yeast two-hybrid screening of TCL1A
The yeast two hybrid screening was performed as previously
described [21]. Briefly the yeast reporter strain HF7c was
transformed by the lithium acetate method with the bait plasmid
pGBT10-TCL1A. After selection and transformation with a
peripheral blood mononuclear cell cDNA library cloned into the
pGAD plasmid, approximately 2.10
6 clones were screened for
HIS+bGAL+ colonies. Out of the 30 HIS+bGAL+ colonies
sequenced, 28 corresponded to the 735 nucleotides at the 39 end of
IkBa transcripts.
Binding analysis through retention by glutathione-
sepharose-bound GST-TCL1A
Recombinant GST-TCL1A and GST-MTCP1 were expressed
in E. coli, bound to glutathione-sepharose beads (Pharmacia), and
placed into Handee Centrifuge Columns. Unbound material was
removed by washing the beads four times with 100 column
volumes of TN300 (10 mM Tris, pH 7.4 and 300 mM NaCl).
Beads were incubated for 1 h at 4uC with 3 mg of AKT_PH,
IkB_ank
7CS, or the Drosophila Notch ankyrin-repeat protein and
washed with 15 column volumes with TN300. The bound proteins
were visualized using SDS PAGE gel under denaturing conditions.
Alternatively, GST proteins bound to the beads were incubated
with rabbit reticulocyte lysates containing [
35S]-labeled translated
IkBa or IkBa1–253 (T7 Quick Coupled Transcription/Translation
System, Promega Madison, WI). Equal loading of the GST fusion
proteins was confirmed by Coomassie staining. Input corresponds
to 5% of the total protein content used for the pull-down. Bound
IkBa and IkBa1–253 were recovered in SDS loading buffer,
resolved by 12% SDS-PAGE and analyzed by autoradiography of
dried gels.
Co-immunoprecipitation assay
293 cells were transiently transfected with pCMV2-FLAG-
TCL1A (Sigma-Aldrich, Saint Quentin Fallavier, France) and
pCMV-IkBa, using the calcium phosphate precipitation technique
as described [22]. Cell extracts were incubated with a mouse anti-
Flag antibody (Sigma-Aldrich) for 16 h and then with protein G-
Sepharose (Amersham Pharmacia Biotech) for an additional hour.
The immunocomplexes were recovered by centrifugation, washed
and resolved by SDS-PAGE. The immunoprecipitated proteins
were revealed by immunoblotting and chemiluminescence.
Western Blot analysis
For Western Blot analysis, the native gels were applied to a
PolyScreen PVDF transfer membrane (NEN Life Science
Products). Membranes were treated as suggested by the manufac-
turer, and incubated with mouse anti-IkBa antibody (1 h at room
temperature), followed by membrane washing in the Tris-buffered
saline. Membranes were then incubated with anti-mouse IgG
linked to horseradish (30 min at room temperature). Membranes
were washed following the manufacturer’s directions, and ECL
detection reagents were added. Kodak biomax light film was
exposed to membranes for ,25 s. The positions of the complexes
formed are indicated.
Recombinant protein production
The pET11a expression plasmid for human IkB67–302 (IkB_ank)
was provided by G. Ghosh. The NF-kB family member RELA/
p65, cloned into pGEX2T, was provided by M. Benkirane. IkB
and RELA were expressed and purified as described [23,24].
Human TCL1A and human AKTb PH1–118 (AKT_PH) were
produced as published [14,25]. The Cys-.Ser mutant IkB67–
302
7CS (IkB_ank
7CS) was obtained using Stratagene’s QuikChange
multi-site directed mutagenesis Kit. The purified recombinant
ankyrin domain of the Drosophila signalling protein Notch was
provided by J.-B. Rouget.
Figure 3. ITC analysis. TCL1A at 470 mM was injected into the
measurement cell containing IkB_ank
7CS at 45 mM. The titration was
carried out at 20uC. The upper panel shows the binding isotherm, the
lower panels shows the integrated heats.
doi:10.1371/journal.pone.0006567.g003
TCL1A Interacts with IkB
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6567PAGE gel shift assays
Undenatured (native) polyacrylamide gel electrophoresis (PAGE)
was performed with purified recombinant proteins. Running gels
contained 15% (w/v) polyacrylamide and 0.125 M Tris (pH 6.8).
Stacking gels contained 5% (w/v) polyacrylamide and 0.375 M Tris
(pH 8.8). For additional Western blot analysis, the native gels were
applied to a PolyScreen PVDF transfer membrane (NEN Life
Science Products). Membranes were treated as suggested by the
manufacturer, and incubated with mouse anti-IkBa antibody (1 h
at room temperature), followed by membrane washing in the Tris-
buffered saline. Membranes were then incubated with anti-mouse
IgG linked to horseradish (30 min at room temperature). Mem-
branes were washed following the manufacturer’s directions, and
ECL detection reagents were added. Kodak biomax light film was
exposed to membranes for ,25 s.
Isothermal titration calorimetry (ITC)
Purified TCL1A, IkB_ank
7CS, RELA and AKT_PH were
extensively dialysed in degassed ITC buffer. The TCL1A -
IkB_ank
7CS titrations were carried out in a buffer similar to the
SAXS measurement (10 mM Tris pH 7.4, 300 mM NaCl, 1 mM
b-mercapto ethanol). All other titrations were carried out in
20 mM sodium phosphate pH 7.1, 300 mM NaCl, 2 mM EGTA
and 1 mM b-mercapto ethanol. ITC was performed at 20uC with
a VP-ITC microcalorimeter from MicroCal Incorporated. For the
AKT_PH –TCL1A titration, TCL1A was placed in the 1.4 mL
sample cell at a concentration of 40 mM, and AKT_PH (490 mM)
was injected using 10–15 ml injections every 300 s. For the IkBa–
TCL1A titration, IkB_ank
7CS (45 mM) was kept in the sample cell,
and TCL1A (470 mM) was injected. Competition experiments
were performed by placing equimolar amounts of TCL1A and
Figure 4. SAXS analysis. (a) SAXS curve (red) calculated from the molecular model depicted in b, fitted to SAXS data (black). (b) Best-scored
SASREF model (surface representation). The TCL1A dimer (taken from PDB entry 1JSG [14]) is shown in two shades of violet. The AKT_PH binding sites
of TCL1A (determined previously by NMR mapping [5]) are coloured yellow. IkB_ank (taken from PDB entry 1NFI [12]) is shown in blue. The
disordered 20 C-terminal tail residues of IkB_ank (dark blue), and 7 N-terminal residues of TCL1A (light pink) were not included in the crystal
structures. These fragments were modelled placed by SASREF as described in the Materials and Methods section. Because the dimensions of the ab
initio GASBOR envelope (pink spheres) suggested that the 20 residues C-terminal tail residues of IkB_ank are pinned back onto the ankyrin repeats,
this constraint was used in SASREF runs. We speculate that hydrophobic tail residues (such as F295 and F298) may cover hydrophobic surfaces on the
ankyrin repeats that are also used by NF-kB. (c) The SASREF model is superimposed onto the ‘filtered’ average envelope (grey spheres) which was
calculated by DAMAVER (file ‘damfilt’) from the 20% top SASREF solutions. The superimposition in DAMAVER was achieved allowing use of
enantiomers. At the low resolution used, models where the C-terminus of the left IkB_ank molecule points down, and the right one up (using the
orientation of the lower panel) resemble enantiomers of the model displayed. Since SAXS is unable to distinguish between enantiomers, models with
both IkB_ank orientations were found among the top 20% best scored SASREF models; the orientation of the model displayed is used by 70% of the
top 20% solutions, and may therefore be more likely.
doi:10.1371/journal.pone.0006567.g004
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7CS in the sample cell, and injecting AKT_PH. For all
protein-protein titrations, control experiments were performed
where the corresponding protein was injected in buffer alone. The
resulting heats were subtracted from the protein-protein titrations
prior to analysis. Data were fitted with Microcal Origin software.
SAXS analysis
Data used for this SAXS analysis were collected at beamline
X33, at DESY, EMBL, Hamburg, at 10uC, l=1.5 A ˚. Additional
preliminary data were collected at the ESRF beamline ID14-3.
For SAXS analysis of the TCL1A:IkB_ank
7CS complex, the
partners were pre-purified individually, then mixed in a 1:1 ratio,
and applied to a S200 size-exclusion column (Pharmacia). Only
eluted fractions corresponding to the 262 TCL1A:IkB_ank
7CS
dimer were used for SAXS. Samples were kept in 10 mM Tris,
pH 7.4, 300 mM NaCl, 1 mM b-mercapto ethanol and supple-
mented with 5 mM DTT prior to exposure. Data collected on
purified TCL1A:IkB_ank
7CS at 1 and 7 mg/ml were merged to
combine the aggregate-free low resolution-part of the 1 mg/ml
scattering curve with the reduced noise at high resolution of the
7 mg/ml data. Data analysis, ab initio shape calculations, and rigid
body docking were performed using programs by S. Svergun and
colleagues (PRIMUS, GNOM, DAMMIN, CRYSOL, DAMA-
VER and SASREF [13,16,26–28]). For GASBOR different q
ranges (0.020–0.45 A ˚ 21 or 0.028–0.40 A ˚ 21) gave very similar
results. For SASREF rigid body docking, P2 symmetry was used.
The TCL1A dimer was obtained from the PDB entry 1JSG [14]),
and this dimeric arrangement was kept fixed during rigid body
docking. IkB_ank was obtained from PDB entry 1NFI [12]. The
regions not included into the crystallographic models (7 N-
terminal residues for TCL1A, and 20 C-terminal residues for
IkB_ank) were modelled as extended unstructured regions and
included as rigid fragments in SASREF modelling. For this, the 20
C-terminal residues of IkB_ank were divided into two rigid 10-
residue fragments. The fragments forming one polypeptide chain
were connected using the constraint that connecting residues lie
within 4.0 A ˚ of each other. SASREF models for different q ranges
(0.020–0.40 A ˚ 21 or 0.028–0.40 A ˚ 21) were very similar.
Supporting Information
Figure S1 Binding assays. (a) Glutathione-sepharose beads
containing GST_TCL1A alone, or GST_TCL1A and indicated
ligands, were washed and analysed by SDS PAGE gels as
described in Supplementary Methods. Notch ank has the same
molecular weight (26 kDa) as IkB_ank. (b) Native gel shift assays,
stained with coomassie blue, or (c) revealed by Western blotting,
using a mouse anti-IkBa antibody.
Found at: doi:10.1371/journal.pone.0006567.s001 (0.30 MB TIF)
Figure S2 Supporting ITC data. All experiments were per-
formed at 20uC. Upper panels show the binding isotherms (black)
and their control experiments (blue) where the syringe content was
injected into the cell containing only buffer. Lower panels show
integrated heats, after subtraction of heats from control experi-
ments (dots). The black lines represent least-square fits of data. (a)
ITC binding isotherm obtained when AKT_PH was injected into
the TCL1A-containing cell. (b) ITC binding isotherm for
AKT_PH injected into the cell containing the TCL1A:Ik-
B_ank7CS complex.
Found at: doi:10.1371/journal.pone.0006567.s002 (0.19 MB
DOC)
Figure S3 SAXS Distance distribution [P(r)] and SASREF
results. (a) P(r) distance distribution, and (b) fit of best GASBOR
model to data (q=0.02–0.45 A ˚ 21).
Found at: doi:10.1371/journal.pone.0006567.s003 (0.06 MB
DOC)
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